Sorrento Selects T-VIVA-19 as a Targeted Protein Vaccine Candidate Against COVID-19
Shots:
- The company has published the preclinical data from its COVID-19 vaccination program- leading to the introduction of T-VIVA-19 as novel targeted protein vaccine
- If approved- Sorrento will deploy its cGMP manufacturing facility- capable of producing bulk drug substance rS1-Fc for up to 100M doses/ month- with on-site scale-up potential to meet the required demand
- T-VIVA-19 is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc (rS1-Fc). The company is planning for clinical trial clearance for the therapy while preparing for large scale manufacturing and commercial distribution in parallel
Click here to read full press release/ article | Ref: Sorrento Therapeutics | Image: Twitter
Related News: Sorrento and the University of Texas Medical Branch Collaborate for the Preclinical Testing of COVID-19 Therapeutic Candidates
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com